Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors

Editor’s Take: A cell-free approach to manufacturing can shorten DNA production timelines compared to traditional plasmid manufacturing.

Genezen is offering drug developers access to 4basebio’s synthetic DNA, developed specifically for viral vector applications, in an expanded collaboration.

The non-exclusive agreement covers 4basebio’s research use only, high-quality, good manufacturing practice (GMP)-grade development and clinical programs, known as hpDNA.

Advantages of Synthetic DNA

4basebio says its enzymatic, cell-free DNA manufacturing process eliminates bacterial backbone sequences and antibiotic resistance genes from DNA starting material.

Regarding adeno-associated virus (AAV) production, the hpDNA template demonstrates comparable titers to plasmid DNA. However, this platform requires approximately 30% less DNA mass and transfection reagent. According to 4basebio, this reduces material requirements and associated costs, and supports efficiency and scalability.

Additionally, a cell-free approach to manufacturing has potential to shorten DNA production timelines, versus traditional plasmid manufacturing.

The companies say this will help developers move more efficiently from sequence, to viral vector production, to the clinic.

4basebio and Genezen in Sync

4basebio Chief Commercial Officer Christine Wolosin said the Genezen arrangement reflects a commitment to pairing proprietary technology with like-minded partners.

“Synthetic DNA is becoming a critical enabler of genetic medicine,” Wolosin said. Genezen’s leadership … combined with growing demand we’re seeing from drug developers … speaks to where this industry is heading. 4basebio is focused on giving drug developers a manufacturing platform upon which they can confidently build their clinical programs.”

Also commenting, Genezen Chief Technical and Commercial Officer Susan D’Costa.

“4basebio’s approach to synthetic DNA represents an exciting advancement in the tools available to viral vector developers,” D’Costa said. “Combining innovative technologies with process and manufacturing expertise, we have an opportunity to help developers build more efficient, scalable strategies.”